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ABSTRACT
Comorbidity measurements have recently been used to improve estimation of tolerance to allogeneic
hematopoietic cell transplantation (HCT). We sought to determine the independent effect of comorbidity
and performance status on HCT outcome and to devise a simple risk classification system for transplant-
related mortality. We analyzed 105 consecutively enrolled patients who underwent HCT and received
reduced intensity conditioning with fludarabine, melphalan, and alemtuzumab. Comorbid conditions were
tabulated using 2 scales, the Charlson Comorbidity Index (CCI) and the Kaplan-Feinstein Scale (KFS).
Comorbid conditions were found in 47% of patients by the KFS and in 27% by the CCI (P < .001). Using
the Eastern Cooperative Oncology Group Performance Status (PS) scale, 34% had a PS score >0 (range,
0-2). A simple scale combining the KFS and PS enabled separation of high- from low-risk patients, with
6-month cumulative incidences 50% and 15%, respectively for transplant-related mortality (P  .001) and
enhanced prognostic power over the CCI alone (P  .018). Prospective studies evaluating more compre-
hensive functional and comorbidity measurements are warranted.
© 2006 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
The toxicities of allogeneic hematopoietic stem
ell transplantation (HCT) historically have re-
tricted eligibility to younger and healthier patients.
educed intensity conditioning regimens, enhanced
upportive care, and more tolerable immunosuppres-
ion have facilitated applying HCT to previously ineli-
ible recipients [1]. Despite these advances, toxicity re-
ains a major barrier, highlighted by nonrelapse or
ransplant-related mortality (TRM) that ranges from
% to 55% [2-13]. This highly variable TRM may
elate in part to study population heterogeneity and
election bias, particularly among older subjects. Ac-
urate estimation of transplantation tolerance has
merged as an essential issue in weighing the risk/
eneﬁt ratio of HCT [14,15]. Identifying prognostic g
54actors also facilitates comparisons among study pop-
lations and generalization of results [16,17].
Standard factors considered for transplantation el-
gibility and/or tolerance include age, donor match-
ng, and objective measurements of single organ func-
ion (eg, pulmonary function tests). In addition, or as
n alternative, summary scores of comorbid condi-
ions have recently been adapted [18]. Numerous re-
iable and validated instruments exist. Among them,
he Charlson Comorbidity Index (CCI) has found the
ost widespread use and has signiﬁcant power to
redict toxicity and survival in cancer patients. Co-
orbidity, primarily when employing the CCI, has
hown only modest prognostic value for hematopoi-
tic cell transplant recipients [10,19-21]. The Seattle
roup recently proposed a revised transplant-speciﬁc
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Comorbidity in Transplantation 955omorbidity index for HCT based on the CCI that
as demonstrated improved prognostication [22].
Functional status represents a domain in addition
o comorbidity to measure patients’ health and may be
ndependent and superior to comorbidity in predict-
ng outcome [23-28]. In oncology, functional status is
sually captured by using simple scales of subjective
erformance status (PS), such as the Karnofsky or
astern Cooperative Oncology Group scales. Al-
hough simple, PS powerfully predicts outcome after
CT [10,29,30]. Even after reduced intensity condi-
ioning, minor PS limitations result in inferior survival
15,21].
We sought to delineate the independent effect of
omorbidity and PS on TRM in a group of uniformly
reated patients after HCT. We devised a simple
rognostic index that incorporated comorbidity and
S, which allowed identiﬁcation of patients at high
isk for TRM.
ETHODS
atients
All patients were enrolled on a single treatment
rotocol that has been previously published [21]. The
niversity of Chicago institutional review board ap-
roved the protocol and all patients provided written
nformed consent. The protocol included patients
ith high-risk or advanced hematologic malignancies
ho were undergoing allogeneic HCT from Decem-
er 2001 until December 2004. Major eligibility cri-
eria included Eastern Cooperative Oncology Group
ECOG) score 2 (or Karnofsky Performance Status
core 60%), total bilirubin level 2 mg/dL, and
reatinine level 1.5 times normal. Although many
atients were ineligible for standard myeloablative
onditioning, the preference for this regimen rested
ith the treating physician and patient.
omorbidity and Performance Status
Data from medical records were extracted to iden-
ify comorbid illnesses and PS. We used the PS closest
o transplant conditioning, typically derived from out-
atient clinic notes. PS scores used the ECOG score
f 0-4, with conversion of Karnofsky PS to an ECOG
S score when needed. Two simple and validated
cales amenable to chart review were used to tabulate
omorbidity, the CCI and the Kaplan-Feinstein Scale
KFS) [31-33] (Tables 1 and 2). Each scale assigns
oints for a variety of comorbid conditions ascertained
y medical history, rather than laboratory or objective
esting. KFS also grades comorbidity from 1 to 3 for
ach organ system impaired. Although potentially
ore sensitive, KFS may be more difﬁcult to apply
34]. Hematologic malignancy was assigned no points
ecause this represented the primary indication for lCT. Thus, scores of 0 deﬁned patients without
corable comorbid conditions, after excluding hema-
ologic malignancy. Prior malignancy that was not the
ndication for HCT was scored (eg, breast cancer).
ung Function and Cardiac Function
Lung function was estimated by using the pre-
ransplantation diffusion capacity of the lung for car-
on monoxide (DLCO). When necessary, DLCO was
djusted for hemoglobin concentration. Left ventric-
lar ejection fraction (EF) was measured with ﬁrst-
ass radionuclide angiocardiography, although echo-
ardiography was occasionally used.
LA Matching, Donors and Stem Cell Processing
Patients and donors were matched for HLA-A,
LA-B, HLA-C, and HLA-DRB1. Sibling donors
ere matched with at least low-resolution techniques.
igh-resolution sequencing methods were used for
nrelated donor/recipient pairs. Acceptable donors
ere related or unrelated donors had 1 antigen mis-
atch at the loci studied. Sibling donors underwent
tem cell mobilization using 5 g/kg of granulocyte
olony-stimulating factor (G-CSF) subcutaneously
wice daily for 5 consecutive days, with peripheral
lood stem cell collection initiated on day 4 and con-
inued until a target of 5  106 CD34 cells/kg
ecipient weight was reached. For unrelated donors,
-CSF–mobilized peripheral blood stem cell collec-
ion was requested, although bone marrow harvests
ere accepted at the preference of the donor or col-
able 1. Scoring of Charlson Comorbidity Index [31]
Comorbid Condition Points
yocardial infarction 1
ongestive heart failure 1
eripheral vascular disease 1
erebrovascular disease 1
ementia 1
hronic pulmonary disease 1
onnective tissue disease 1
lcer disease 1
ild liver disease 1
iabetes (mild) 1
iabetes with end-organ damage 2
emiplegia 2
oderate or severe renal disease 2
ny tumor 2
eukemia* 2
ymphoma* 2
oderate or severe liver disease 3
etastatic solid tumor 3
IDS 6
otal score (add points for each condition)
IDS indicates acquired immunodeﬁency syndrome.
Not scored as hematologic malignancy represents primary indica-
tion for therapy.ection center.
Table 2. Scoring of Kaplan-Feinstein Scale [33]
Comorbid Condition Grade 3 Grade 2 Grade 1 Grade
Hypertension Severe or malignant; papilledema;
encephatopathy; or diastolic pressure
>130 mm Hg
Diastolic pressure 115-129 mm Hg; or at any level
below 130, with secondary cardiovascular or
symptomatic effects such as headaches, vertigo,
epistaxis
Diastolic pressure 90-114 mm Hg, without
secondary effects or symptoms
1 2 3
Cardiac Within past 6 months: congestive heart
failure, myocardial infarction,
significant arrhythmias, or
hospitalization required for angina
pectoris or angina-like chest pain
Congestive heart failure >6 months ago; or angina
pectoris not requiring hospitalization
Myocardial infarction >6 months ago;
ECG evidence of coronary artery
disease; atrial fibrillation
1 2 3
Cerebral or psychic Recent stroke, comatose state, or suicidal
state
Old stroke, with residua; recent transient
ischemic attacks; or recent episode of status
epilepticus
Old stroke without residua; past transient
ischemic attacks; or frequent epileptic
seizures
1 2 3
Respiratory Marked pulmonary insufficiency (ie,
cyanosis, CO2 narcosis); or recurrent
status asthmaticus
Moderate pulmonary insufficiency (ie, dyspnea on
slight exertion); recurrent pneumonia; or
recurrent asthmatic attacks with chronic
obstructive pulmonary disease
Mild pulmonary insufficiency; recent
active tuberculosis; chronic lung disease
manifested only on X-ray or function
tests; or recurrent asthmatic attacks
without underlying lung disease
1 2 3
Renal Uremia; renal decompensation without
secondary anemia, edema,
hypertension
Azotemia, manifested by elevated BUN (>25
mg%) and/or creatinine (3.0 mg%) without
secondary effects; nephrotic syndrome;
recurrent renal infections; hydronephrosis
Proteinuria (tests of 3 or 4 on >2
urinalyses, or excretion >1 g on 24-h
urine collection); recurrent lower
urinary infections or renal stones
1 2 3
Hepatic Hepatic failure (ascites, icterus,
encephalopathy); or esophageal
varices
Compensated hepatic failure (cutaneous spiders,
palmary erythema, hepatomegaly or other
clinical evidence of chronic liver disease)
Chronic liver disease manifested on
biopsy or by persistently elevated BSP
(>15% retention) or bilirubin (>3 mg%)
1 2 3
Gastrointestinal Recent major bleeding controlled by
>6 U of blood transfusion
Moderate bleeding, requiring transfusion but <6 U
of blood; recent acute pancreatitis; or chronic
malabsorption syndrome
Slight bleeding, not requiring transfusion;
episodes of symptomatic cholelithiasis;
chronic pancreatitis; or peptic ulcer
1 2 3
Peripheral vascular None Recent amputation or gangrene of extremity Old amputation; intermittent claudication 1 2 3
Malignancy* Uncontrolled Controlled (ie, successful previous resection or
other therapy); Kaposi sarcoma
None 1 2 3
Locomotor impairment Bed-to-chair existence Moderately impaired (confined to home, nursing
home, or convalescent setting)
Slightly impaired (some limitation of
activity)
1 2 3
Alcoholism Severely decompensated (ie, >1 episode
of delirium tremens or alcoholic
seizures)
Moderately decompensated (ie, single episode of
delirium tremens or seizures); recurrent
hospitalization for alcohol-associated ailments
such as gastritis or pancreatitis; nutritionally
caused cachexia or anemia; or significant
behavior problems
Mildly decompensated (ie, “drinking
problem”); may have had
hospitalizations for acute intoxication
but no documented alcohol-associated
aliments
1 2 3
Miscellaneous Uncontrolled systemic “collagen
disease” (eg, lupus erythematosus)
Controlled systemic “collagen disease” Recurrent epistaxis requiring transfusion;
chronic active infection not specified
elsewhere
1 2 3
Total score (add points for each condition)
ECG indicates electrocardiographic; BSP, ??; BUN, serum urea nitrogen.
*Hematologic malignancy not scored when it represents the primary indication for therapy.
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Comorbidity in Transplantation 957reatment Regimen
All patients received ﬂudarabine 30 mg/m2/day
ntravenously (IV; 150 mg/m2 total) and alemtuzumab
0 mg/day IV (100 mg total) for 5 consecutive days
days 7 through 3) and melphalan 140 mg/m2 IV
n day 2. Post-transplantation immunosuppression
onsisted of tacrolimus from day 2 until day 100,
argeting a trough level of 5-15 ng/mL. Tapering over
weeks began after day 100 unless patients had de-
eloped signiﬁcant graft-versus-host disease.
upportive Care
Standard supportive care included G-CSF 5
g · kg1 · d1 subcutaneously starting on day 1 after
tem cell infusion until the neutrophil count increased
o10 109/L. Infection prophylaxis included bac-
erial prophylaxis with levoﬂoxacin or gatiﬂoxacin,
neumocystis carinii prophylaxis with trimethoprim/
ulfamethoxazole, and fungal prophylaxis with ﬂucon-
zole. When available, high-risk patients such as those
ith prior or suspected fungal infection received vori-
onazole. All patients (including seronegative donor
nd/or recipient pairs) [16] were screened weekly for
ytomegalovirus (CMV) viremia until day 120 and
reated with ganciclovir upon detection of CMV vire-
ia. CMV prophylaxis for seropositive donor and/or
ecipients initially included ganciclovir 5 mg/kg IV
aily from conditioning start until day 3, followed
y acyclovir 10 mg/kg every 8 hours IV until hospital
ischarge, and acyclovir 800 mg orally 3 times daily
ntil day 180. The high incidence of CMV reactiva-
ion prompted a policy change to use valacyclovir 2 g
rally 4 times daily from discharge until day 210
35,36].
tatistical Considerations
Chi-square test was used to test for associations
etween groups based on age, HLA matching, prior
ransplantation, PS, comorbidity score (KFS and
CI), and cardiac and pulmonary functions. The dif-
erence in the proportions of patients scoring posi-
ively on 1 of the comorbidity scales (KFS and CCI)
ut not the other was tested with the McNemar test.
he proportions of patients scoring positively on KFS
nd CCI were compared with generalized estimating
quations [37].
Time to event was counted from the day of stem
ell infusion (day 0). Overall survival (OS) was esti-
ated with the Kaplan-Meier method, and groups
ere compared with the log-rank test [38]. TRM was
eﬁned as any death occurring in the absence of pro-
ression or recurrence of the underlying disease.
RM and relapse-related deaths were treated as com-
eting risks; cumulative incidences and 95% conﬁ-
ence intervals (CIs) for both were estimated. The
umulative incidence of 100- and 180-day TRMs were nompared with a z test [39]. The Cox proportional
azards regression was used for multivariate analyses
f OS and TRM [40]. Univariate models were used
o estimate TRM hazard rates (HRs), 95% CIs, and
values on TRM (Table 3). Multivariate models as-
essed the effect of each prognostic factor listed in
able 4, after adjusting for donor mismatch, prior
ransplantation, and age.
To further assess the predictive ability of the pro-
osed risk-grouping system, C statistics [41] were
sed. A value of 1 indicates perfect predictive discrim-
nation, whereas a value of 0.5 indicates no predictive
bility (ie, no better than chance). Pairs of observa-
ions where the shorter time was censored were ex-
luded as being noninformative. To compare C sta-
istics, we calculated a z test and standard error
stimates based on 500 bootstrap replications. When
omputing the C statistics for TRM, deaths due to
isease were treated as censored. C statistics for pre-
icting death from any cause or due to treatment
TRM) during the ﬁrst 100 and 180 days were com-
uted as the area under the receiver operating char-
cteristic curve [42] and were compared using a z test
nd asymptotic variance estimates.
All P values were 2-sided and considered signiﬁ-
ant if P  .05 for this hypothesis-generating study.
tatistical analysis used STATA 8 [43] and the “cm-
rsk” package [44] available in R (R Development
ore Team, 2005).
ESULTS
atient and Donor Characteristics
Table 5 lists baseline characteristics of the 105
atients. Median age was 52 years (range, 17-70 years)
nd 52% were male. Myeloid malignancy represented
he most common indication for transplantation be-
ause 62% had acute myeloid leukemia, myelodysplas-
ic syndromes (MDS), or chronic myelogenous leuke-
ia. HLA-identical related donors were used in 55%
f cases and matched unrelated donors in 36%. One-
ntigen/allele mismatched related or unrelated donors
ccounted for 9% of cases. Forty-six percent of pa-
ients died. Median follow-up among survivors was
5.5 months (range, 1.4-38 months).
Sixty percent of patients were 50 years of age
nd only 14% were 40 years. PS scores of 0, 1, and
were present in 70 (67%), 26 (25%), and 9 (9%),
espectively. PS score 1 was present in 25 of 63
atients (40%) who were 50 years of age compared
ith 10 of 42 (24%) who were 50 years (P  .09).
edian left ventricular EF was 57% and 35% had an
F 55% [45]. Only 3 subjects (2.9%) had an EF
40%. Median DLCO was 85%. Thirty-two percent
ad an abnormal DLCO of78% [46]. Older age was
ot associated with abnormal EF (P  .77) or DLCO
(
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A. S. Artz et al.958P  .95). Nineteen patients had previously under-
one an autologous HCT, 2 of whom had received 2
ransplants. One patient had previously undergone an
llogeneic transplantation.
omorbidity Scores
Applying the CCI showed1 comorbid condition
n 27% (28 of 105) of patients. KFS identiﬁed 1
omorbid condition in 47% (49 of 105) of patients.
able 3. Univariate Analysis of Pretransplantation Factors for TRM
Characteristic
Cumulat
Incidence
ge >50 y
Yes 29
No 15
onor, unrelated
Yes 19
No 24
onor, mismatch
Yes 49
No 22
rior transplantation
Yes 50
No 19
LCO <78
Yes 28
No 22
jection fraction <55%
Yes 21
No 25
harlson Comorbidity Index score >1
Yes 26
No 22
aplan-Feinstein Scale score >1
Yes 33
No 18
erformance status score >1
Yes 34
No 18
RM indicates transplant-related mortality; HR, hazard ratio; CI
monoxide.
able 4. Multivariate Analysis of Pretransplantation Factors on Outcom
Transp
Characteristic* HR
ge >50 y 3.3
onor, unrelated 1.13
onor, mismatch 3.16
rior transplantation 4.6
LCO <78 1.4
jection fraction <55% 0.92
harlson Comorbidity Index score >1 0.94
aplan-Feinstein Scale score >1 2.0
erformance status score >1 2.3
isk group, High 4.6Adjusted for age, HLA mismatch, and prior transplantation, when applichis difference was highly signiﬁcant (P  .0001).
cores 2 were present in 11% (12 of 105) by CCI
ompared with 24% (25 of 105) by KFS (P  .004).
ive patients with no comorbidity by KFS scored a
oint by CCI, whereas 26 (25%) were assigned points
y KFS but not by CCI (P  .0002).
Age was associated with increased comorbidity as
easured by CCI or KFS. Among patients who were
50 years of age, a comorbid condition was found in
HR 95% CI P
2.35 1.0-5.5 .05
1.00 0.47-2.1 .99
2.16 0.75-6.3 .16
3.02 1.4-6.6 .005
1.35 0.63-2.9 .44
0.79 0.34-1.9 .59
1.54 0.69-3.4 .29
2.28 1.1-4.9 .04
2.39 1.1-5.0 .02
dence interval; DLCO, diffusion capacity of the lung for carbon
lated Mortality Overall Survival
P HR P
.008 2.3 .012
.76 1.79 .05
.04 2.52 .039
.0004 3.1 .001
.35 1.9 .03
.84 1.4 .31
.88 1.5 .2
.079 2.5 .0038
.03 2.3 .0056
.0002 3.2 .0001ive
(%)
, conﬁe
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Comorbidity in Transplantation 9597% (23 of 63) by CCI and 57% (33 of 63) by KFS. In
ounger subjects, a comorbid condition was identiﬁed
n 12% (5 of 42) by CCI and 31% (13 of 42) by KFS.
he differences for CCI and KFS between older and
ounger patients were signiﬁcant (P  .005 for CCI
able 5. Patient Characteristics (n  105)
Characteristic n (%)
ge, y
<40 15 (14)
40-49 27 (26)
50-59 34 (32)
>60 29 (28)
ex
Female 50 (48)
iseases
AML 52 (50)
MDS 9 (9)
CML 4 (4)
CLL 3 (3)
ALL 5 (5)
NHL 15 (14)
Hodgkin lymphoma 4 (4)
Myeloma 5 (5)
Other* 8 (8)
onors†
Sibling
Matched 58 (55)
Mismatched 4 (4)
Unrelated Donors
Matched 38 (36)
Mismatched 5 (5)
rior transplantation
>1 prior transplantation 20 (19)
ealth status
Performance status score
0 70 (68)
1 26 (25)
2 9 (9)
omorbidity
Pulmonary (n  101)
DLCO <78, corrected 35 (35)
Cardiac (n  103)
Ejection fraction <55% 33 (32)
Charlson Comorbidity Index score
0 77 (73)
1 16 (15)
>2 12 (11)
Kaplan-Feinstein Scale
0 56 (53)
1 24 (23)
>2 25 (24)
ML indicates acute myeloid leukemia; MDS, myelodysplastic syn-
dromes; CML, chronic myelogenous leukemia; CLL, chronic
lymphocytic leukemia; ALL, acute lymphoblastic leukemia;
NHL, non-Hodgkin lymphoma.
Other includes aplastic anemia and/or paroxysmal nocturnal he-
moglobinuria (PNH) (n  3), chemotherapy induced aplasia (n
 1), mast cell leukemia (n  2), dendritic cell tumor (n  1),
and sickle cell anemia (n  1).
Matched donors were matched for at least HLA-A, HLA-B,
HLA-C, and HLA-DRB1 loci. Mismatches are for a single
antigen/allele.nd P  .008 for KFS). †Abnormal KFS scores occurred in 21 of 35 pa-
ients (60%) with a PS score of 1-2 and in 40%
ubjects (28 of 70) with a PS score of 0. Thus, abnor-
al KFS scores occurred more commonly in patients
ith an abnormal PS score (P .053) but a signiﬁcant
inority of patients with a normal PS score had a
omorbidity by KFS.
ransplant-Related Mortality
Cumulative incidences of TRM were 16.4% (CI,
0%-24%) at 100 days and 23.5% (CI, 16%-32%) at
80 days. Disease-related mortalities were 2.0% (CI,
.37%-6.2%) at 100 days and 8.1% (CI, 3.8%-14%)
t 180 days. Thus, most deaths within the ﬁrst 6
onths after transplantation resulted from TRM
ather than from disease progression (P  .002). In
nivariate analysis (Table 3), increased TRM was as-
ociated with prior transplantation (P  .005), older
ge (P  .05), KFS score 1 (P  .04), and PS score
1 (P  .02).
verall Survival
Median OS was 16.9 months. OS was 82% (CI,
3%-89%) at 100 days, 69% (CI, 59%-77%) at 180
ays, and 58% (CI, 47%-67%) at 1 year.
isk Group
We ﬁrst sought to determine whether comorbid-
ty and PS could enhance estimation of TRM from
tandard prognostic factors. We chose KFS over CCI
ecause KFS was more sensitive and more strongly
ssociated with TRM in univariate analysis.
The few patients with very signiﬁcant limitations
n comorbidity (KFS score 2, n  5) or PS (PS
core 2, n  9) were considered high-risk patients.
he vast majority of patients (88%, 92 of 105), how-
ver, scored normal (KFS score 0) or intermediate on
FS (KFS score 1-2) and PS (PS score 0-1) as shown
n Table 6. This group may be the most challenging to
urther stratify risk for HCT. After excluding the very
igh-risk patients (KFS score 2 and/or PS score
), an intermediate KFS (KFS score 1-2) showed a
onsigniﬁcant trend toward higher TRM compared
ith a normal KFS (P  .12). An intermediate PS
able 6. Risk Group Categorization
Kaplan-Feinstein Scale
PS† 0 1-2 3 Total
0 42 26 2* 70
1 11 13* 2* 26
2 3* 5* 1* 9
Total 56 44 5 105
High-risk group.
Eastern Cooperative Oncology Group Performance Status Scale.
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A. S. Artz et al.960PS score 1) demonstrated a stronger trend toward
ncreased TRM compared with a normal PS (P 
045). Recognizing that functional measurements, PS
mong them, have independent and possibly superior
redictive value to comorbidity measurements in
ther cohorts, we combined KFS and PS [23-28]. An
ntermediate score for PS and KFS (n  13) was
ssociated with increased TRM compared with having
n abnormality on 1 scale or no abnormalities on
ither scale (n  79, P .0019).
Capitalizing on the prognostic value of combining
FS and PS for the patients with intermediate scores,
e constructed a new risk group score (Table 6).
igh-risk patients had a KFS score 2, a PS score
1, or an abnormality on KFS and PS. Twenty-six
atients fulﬁlled these criteria. These 26 (25%) high-
isk patients had a signiﬁcant increase in TRM (HR,
.1; CI, 2%-8.6%; P  .0002; Figure 1) compared
ith other patients. The cumulative incidence of
RM at 6 months was 50% for the high-risk group
95% CI, 29%-68%) compared with 15% for the
ow-risk group (95%CI, 7.7%-23%; P .001; Table 7).
To further determine the additional prognostic
alue of risk groups, we analyzed the risk group clas-
iﬁcation after stratifying for standard adverse prog-
ostic factors such as advanced age or prior transplan-
ation. Among older patients, 19 of 63 (30%) were in
he high-risk group compared with 7 of 42 (17%)
ounger subjects (P  .12). Six-month TRM was
ncreased for the high-risk group when restricting the
nalysis to older (P  .055) or younger (P  .017)
atients. Similarly, high-risk group was strongly asso-
iated with inferior OS in older (P .0035) but not in
ounger (P  .11). patients When analyzing risk
roup according to prior transplantation, 6-month
RM among those without prior transplantation was
lso signiﬁcantly worse for the high-risk group (P 
igure 1. Six-month cumulative incidence of transplant-related
ortality by risk group.004). Interestingly, only 4 of 20 patients who received
Hprior transplant were classiﬁed into the high-risk
roup. All 4 developed TRM. Only 6 of 16 (37.5%)
ho were allocated to the low-risk group had TRM
ho received a prior transplant.
ultivariable Analysis
To analyze the independent effects of comorbidity
nd PS, adjustment was made for the standard prog-
ostic variables of age, donor mismatch, and prior
ransplantation. No adjustment was made for unre-
ated donors because TRM did not differ for unrelated
r related donors (P  .99). DLCO, EF, and CCI did
ot affect TRM after adjustment. Similarly, OS was
ot inﬂuenced by EF and CCI after adjustment, al-
hough DLCO was associated with inferior OS (P 
03). An abnormal KFS score trended toward statisti-
al signiﬁcance for TRM (P .079) but more strongly
nﬂuenced OS (P  .0038). After adjustment, PS in-
uenced TRM (P  .03) and OS (P  .0056). Risk
roup strongly predicted outcome in multivariable
nalysis. High-risk group patients fared signiﬁcantly
orse for TRM (HR, 4.6; P  .0002) and OS (HR,
.2; P  .0001).
Statistic
The CCI has been the most widely applied co-
orbidity measurement and most commonly used
ool in HCT studies. We used C statistics to compare
he proposed risk group with CCI. Risk group enabled
igniﬁcantly better prediction of TRM (C, 0.66; CI,
.57-0.76) than did CCI (C, 0.53; CI, 0.44-0.62; P 
018).
ISCUSSION
HCT has been increasingly applied to patients at
ncreased risk for transplantation complications such
s those with advanced age, comorbidities, and/or
rior transplantation [4,10,12,21,47,48]. Accurate es-
imation of HCT toxicity (and vice versa, probability
f HCT tolerance) has become essential. Combining
erformance status to a comorbidity score enabled
dentifying patients at high risk of TRM.
The prognostic effect of standard factors such as
ecipient age, donor matching, and prior transplanta-
ion have been studied, but these factors lack discrim-
natory power and are insufﬁcient to estimate HCT
able 7. Transplant-Related Mortality By Day 180 for Risk Groups
Risk
Group n
TRM at Day 180
Cumulative Incidence (%) 95% CI P
ow 79 15 7.7-23 .001
igh 26 50 29-45
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Comorbidity in Transplantation 961olerance. Pretransplantation measurement of cardiac
nd pulmonary functions has long been standard prac-
ice but is of limited value in predicting TRM as
onﬁrmed by our analysis [49].
We were interested in devising a simple prognos-
ic score by using information readily available before
CT by analyzing PS and comorbidity on transplant
olerance after a uniform reduced intensity condition-
ng regimen. The characteristics of our study cohort
ere typical of the high-risk characteristics in series of
ther reduced intensity conditioning regimens. Sixty
ercent were 50 years of age, 19% received prior
ransplants, and 51% had 1 comorbid condition by
he CCI or KFS.
Tabulating comorbid conditions from the medical
istory into a summary score scale is a well-accepted
ethod of capturing comorbidity. Among cancer pa-
ients undergoing conventional treatment, comorbid-
ty scores help predict outcome [23-28]. The CCI is
he most frequently used in oncology [50] and recently
as been applied in the HCT setting [10,19-22].
We explored the value of another validated and
otentially more comprehensive comorbidity index
uited to chart review, the KFS. The KFS demon-
trated enhanced sensitivity by ascertaining comorbid
onditions in 47% of patients compared with 27% by
CI (P  .001). In univariate analysis, TRM was
ffected by KFS (P  .04) but not by CCI (P  .29).
In addition to comorbidity, health status may be
auged by using functional status measurements such
s PS. Abnormal PS has shown remarkably consistent
alue for increased TRM and mortality after HCT
10,15,25,29,30]. Using the ECOG PS scale of 0-4,
ost subjects in our series scored as fully functional
PS score 0) or mildly symptomatic (PS score 1). Only
of 105 patients were given a PS score 1 (eligibility
equired a PS score of 0-2). Even with the minimal
ange of PS scores, a PS score of 1-2 adversely affected
RM in univariate (P  .02) and multivariate (P 
03) analyses. These results and previous data support
outinely recording and reporting PS, especially in
atients considered to be at increased risk of HCT-
elated toxicity and mortality. Interestingly, most se-
ies on HCT tolerance in older patients do not report
S [4,12,19,20,51-53].
It is well established that functional status mea-
urements in oncology patients offer independent pre-
ictive value of comorbidity [23-28]. We are unaware
f any data incorporating PS into a score estimating
CT tolerance. We hypothesized that a combination
f PS and a comorbidity score would allow a simple
et reliable method of identifying patients at high risk
or TRM. Patients with high KFS score (ie, 2) and
igh PS score (ie, 2) were considered at high risk for
RM. However, the vast majority of patients had
ormal (PS score 0, KFS score 0) or intermediate (PS fcore 1, KFS score 1-2) scores. Patients scoring inter-
ediate on the KFS and PS were also allocated to the
igh-risk group. This simple dichotomous classiﬁca-
ion schema achieved excellent delineation of patients
t high risk of TRM. The cumulative incidence of TRM
t 6months was signiﬁcantly worse for high-risk patients
50%) than for low-risk patients (15%; P  .001).
Other prognostic factors were explored primarily
o separate the effects of comorbidity and PS from
tandard prognostic factors. Consistent with other re-
orts, prior transplantation, primarily autografting,
igniﬁcantly increased TRM despite a reduced inten-
ity conditioning regimen [5,51,54,55]. Nevertheless,
elonging to the high-risk group predicted far worse
RM and OS, even in patients who had undergone
rior transplantation.
Sixty percent of patients in our study were 50
ears of age. Older age was an adverse prognostic
actor for TRM in univariate analysis (P  .05) and
fter adjusting for prior transplantation and donor
ismatch (HR, 3.3; P  .008). Even in the older
ubjects, risk group added prognostic value in pre-
icting TRM and OS, thus afﬁrming the added
alue of comorbidity and PS to standard prognostic
easurements. Age by itself may be inadequate to
etermine transplantation eligibility or tolerance. We
elieve HCT eligibility should be based on more pre-
ise scores of HCT tolerance rather than chronologic
ge.
Another approach to better estimate HCT toler-
nce applied by the Seattle team was to develop a
roader, more detailed index of comorbidities [22].
he revised comorbidity index divided patient risk
nto low, intermediate, and high. The large sample
ermitted a training set and a validation set. Only in
he high-risk subset (28% of patients) was an increased
RM at 2 years observed (HR, 3.5; 95 CI, 2.0-6.3; no
value provided). The high-risk group as deﬁned by
ur method similarly comprised 25% and had a sim-
lar adjusted HR of 4.2 for TRM (P  .0001). We
elieve the 2 approaches of risk assessment are not
utually exclusive; increased sensitivity through more
omprehensive comorbidity measurements and/or use
f functional measurements will likely promote supe-
ior prognostication.
Several limitations exist in this study. The limited
ample precludes detection of small, but meaningful,
rognostic differences. In contrast, variability and bias
hould have been minimized with the uniform treat-
ent protocol and enrollment over a short period.
etrospective collection of data may diminish sensi-
ivity, especially for identifying comorbid conditions.
he tools themselves also have signiﬁcant limitations.
he KFS and CCI represent comorbidity scales de-
igned for the general medical population, rather than
or patients undergoing HCT. The comorbidity and
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A. S. Artz et al.962S scales also have ceiling effects (the instruments
ay not detect important problems) and lack of dis-
riminative capacity. For example, few patients scored
1 on PS or KFS. Another problem may be the
entral role of PS, a nonobjective test, on placing
atients in the high-risk group. Clinician-rated PS
sing the ECOG or Karnofsky scale has excellent
nterobserver and intraobserver reliabilities [56]. De-
pite its simplicity and promise, our risk group re-
uires validation in other HCT cohorts before being
idely applied.
We anticipate prospective testing employing more
ensitive instruments may permit more accurate esti-
ation of HCT tolerance. For example, prior infec-
ions or comorbid conditions relevant to the condition-
ng regimen selected could be incorporated into an
CT-speciﬁc comorbidity score. Our data afﬁrm the
mportance of using PS and highlight the need to eval-
ate more reﬁned measurements of functional status,
specially in older adults. Abundant data support the
rognostic power of simple measurements of patient
unction, independent of comorbidity, among the gen-
ralized elderly population [57]. The value of the pres-
nce of a caregiver, nutritional status, and inﬂammatory
arkers are other domains not ascertained that warrant
tudy. Whether the additional time and effort of more
xtensive testing offers an advantage in individual de-
ision-making requires investigation. Nevertheless,
etter describing patient characteristics would facili-
ate comparisons and inferences of studies, particu-
arly among older patients, where heterogeneity and
election bias remain highly problematic.
In summary we conﬁrm the prognostic impor-
ance of PS and comorbidity on outcome for patients
ndergoing HCT. Employing a simpliﬁed risk-group
ystem combing the KFS of comorbidity and PS iden-
iﬁed patients at high risk for TRM and inferior sur-
ival. Prospective studies using more sensitive mea-
urements of comorbidity and functional status are
ngoing.
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